| __timestamp | Alkermes plc | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 447875000 | 9136000 |
| Thursday, January 1, 2015 | 483393000 | 5807000 |
| Friday, January 1, 2016 | 519270000 | 5571000 |
| Sunday, January 1, 2017 | 567637000 | 5366000 |
| Monday, January 1, 2018 | 601826000 | 6337000 |
| Tuesday, January 1, 2019 | 693218000 | 11347000 |
| Wednesday, January 1, 2020 | 572904000 | 30419000 |
| Friday, January 1, 2021 | 603913000 | 62176000 |
| Saturday, January 1, 2022 | 218108000 | 52827000 |
| Sunday, January 1, 2023 | 253037000 | 35049000 |
| Monday, January 1, 2024 | 245331000 |
Unlocking the unknown
In the evolving landscape of pharmaceuticals, understanding cost structures is crucial. From 2014 to 2023, Alkermes plc and Ligand Pharmaceuticals Incorporated have shown distinct trajectories in their cost of revenue. Alkermes plc, a leader in biopharmaceuticals, saw its cost of revenue peak in 2019, reaching nearly 70% higher than its 2014 levels. However, by 2023, it had decreased by approximately 63% from its peak, indicating strategic cost management or shifts in production. In contrast, Ligand Pharmaceuticals, known for its innovative drug discovery, experienced a more than sixfold increase in cost of revenue from 2014 to 2021, reflecting its expanding operations. Yet, by 2023, costs had reduced by about 44% from their 2021 high. These trends highlight the dynamic nature of cost management in the pharmaceutical industry, driven by innovation and market demands.
Novo Nordisk A/S vs Alkermes plc: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Merck & Co., Inc. and Alkermes plc's Expenses
Comparing Cost of Revenue Efficiency: Sanofi vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Alkermes plc
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Incyte Corporation and Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Alkermes plc
Alkermes plc vs Veracyte, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Alkermes plc and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: PTC Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Perrigo Company plc vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Ligand Pharmaceuticals Incorporated vs Galapagos NV